X

Trial Profile

A Study of QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer

Status: Discontinued

Phase of Trial: Phase II/III

Latest Information Update: 16 Jan 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Iparomlimab (Primary) ; Carboplatin; Cisplatin; Paclitaxel
Indications Adenocarcinoma; Cervical cancer; Squamous cell cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Qilu Pharmaceutical

Most Recent Events

10 Jan 2024 Status changed from recruiting to discontinued.
04 Dec 2022 Results (n=46 ) presented in a Qilu Pharmaceutical Media Release.
04 Dec 2022 According to a Qilu Pharmaceutical media release, data (n=46 ) were presented at the European Society for Medical Oncology (ESMO) Asia Congress 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com